

Geert D'Haens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8514350/publications.pdf>

Version: 2024-02-01

167
papers

23,038
citations

28274

55
h-index

8167

148
g-index

169
all docs

169
docs citations

169
times ranked

11582
citing authors

#	ARTICLE	IF	CITATIONS
1	Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2010, 362, 1383-1395.	27.0	2,710
2	Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. <i>American Journal of Gastroenterology</i> , 2015, 110, 1324-1338.	0.4	1,425
3	Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. <i>Gastrointestinal Endoscopy</i> , 2004, 60, 505-512.	1.0	1,326
4	Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2017, 376, 1723-1736.	27.0	1,232
5	Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. <i>Lancet, The</i> , 2008, 371, 660-667.	13.7	1,135
6	Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Gastroenterology</i> , 2012, 142, 257-265.e3.	1.3	1,062
7	A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis. <i>Gastroenterology</i> , 2007, 132, 763-786.	1.3	917
8	Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. <i>Gastroenterology</i> , 1999, 116, 1029-1034.	1.3	779
9	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. <i>Gut</i> , 2011, 60, 780-787.	12.1	750
10	Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 2218-2224.	1.9	662
11	Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2779-2789.	13.7	633
12	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017, 66, 839-851.	12.1	630
13	Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. <i>Gastroenterology</i> , 2014, 147, 618-627.e3.	1.3	607
14	Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. <i>Gut</i> , 2007, 56, 1226-1231.	12.1	539
15	Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial. <i>Gastroenterology</i> , 2012, 142, 1102-1111.e2.	1.3	485
16	Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2017, 389, 1699-1709.	13.7	364
17	Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2016, 374, 1754-1762.	27.0	361
18	Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 1825-1834.	13.7	354

#	ARTICLE	IF	CITATIONS
19	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. <i>Gut</i> , 2014, 63, 1381-1392.	12.1	317
20	Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. <i>Gut</i> , 2017, 66, 1049-1059.	12.1	274
21	Development and validation of a histological index for UC. <i>Gut</i> , 2017, 66, 50-58.	12.1	264
22	Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2021, 385, 1280-1291.	27.0	243
23	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1343-1351.e1.	1.3	240
24	Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. <i>Gut</i> , 2014, 63, 433-441.	12.1	222
25	The Role of Centralized Reading of Endoscopy in a Randomized Controlled Trial of Mesalamine for Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 145, 149-157.e2.	1.3	196
26	Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 2123-2138.e8.	1.3	189
27	Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 254-266.	1.3	175
28	Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2020, 158, 562-572.e12.	1.3	173
29	Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 251-258.e2.	4.4	171
30	IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. <i>Gut</i> , 2016, 65, 1447-1455.	12.1	155
31	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jcw176.	1.3	141
32	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jcw177.	1.3	140
33	Acute severe ulcerative colitis: from pathophysiology to clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 654-664.	17.8	129
34	Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. <i>United European Gastroenterology Journal</i> , 2014, 2, 30-37.	3.8	118
35	Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 423-431.e1.	4.4	117
36	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	12.1	108

#	ARTICLE	IF	CITATIONS
37	The Mucosa-associated Microbiota of PSC Patients is Characterized by Low Diversity and Low Abundance of Uncultured Clostridiales II. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 342-348.	1.3	106
38	Long-term safety of vedolizumab for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1353-1365.	3.7	97
39	Impact of disease location on fecal calprotectin levels in Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 841-847.	1.5	93
40	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019, 58, 15-37.	3.5	91
41	Development of Reliable, Valid and Responsive Scoring Systems for Endoscopy and Histology in Animal Models for Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 794-803.	1.3	88
42	Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1170-1181.	3.7	86
43	Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 997-1006.e6.	1.3	86
44	The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 105-119.	1.3	76
45	Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1119-1125.	12.1	74
46	Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 920-929.	1.3	71
47	25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. <i>Gut</i> , 2021, 70, 1396-1405.	12.1	68
48	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 637-646.e11.	4.4	67
49	Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 1082-1092.	3.7	66
50	Reproducibility of histological assessments of disease activity in UC. <i>Gut</i> , 2015, 64, 1765-1773.	12.1	66
51	A phase II study of laquinimod in Crohn's disease. <i>Gut</i> , 2015, 64, 1227-1235.	12.1	66
52	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	1.3	65
53	Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. <i>Current Treatment Options in Gastroenterology</i> , 2018, 16, 129-146.	0.8	64
54	Development of Fibrosis in Acute and Longstanding Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 966-972.	1.3	61

#	ARTICLE	IF	CITATIONS
55	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 145-154.	1.5	61
56	Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 702-710.	17.8	57
57	A Systematic Review of Measurement of Endoscopic Disease Activity and Mucosal Healing in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1850-1861.	1.9	56
58	Safety and Feasibility of Using the Second-Generation Pillcam Colon Capsule to Assess Active Colonic Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1480-1486.e3.	4.4	55
59	The development of a magnetic resonance imaging index for fistulising Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 516-528.	3.7	53
60	Persistent Mesorectal Inflammatory Activity is Associated With Complications After Proctectomy in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 285-293.	1.3	52
61	Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2012, 143, 1461-1469.	1.3	49
62	Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 453-458.	1.5	49
63	Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2022, 162, 26-31.	1.3	48
64	Combination Immunosuppression in IBD. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 539-545.	1.9	45
65	Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 294-306.	8.1	42
66	Anti-interleukin-23 agents for the treatment of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 399-406.	3.1	41
67	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 366.	1.6	40
68	The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1110-1117.	1.5	40
69	Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1018-1029.	3.7	40
70	Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 429-439.	3.1	40
71	Once-Daily MMX® Mesalamine for Endoscopic Maintenance of Remission of Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2012, 107, 1064-1077.	0.4	39
72	Fistulizing Crohn's disease: Diagnosis and management. <i>United European Gastroenterology Journal</i> , 2013, 1, 206-213.	3.8	39

#	ARTICLE	IF	CITATIONS
73	Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 607-618.	1.3	39
74	A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2015, 26, 2085-2091.	1.2	37
75	Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 517-524.	1.3	36
76	Next-Generation Therapeutics for IBD. <i>Current Gastroenterology Reports</i> , 2015, 17, 21.	2.5	35
77	Vitamin D deficiency in Crohn's disease and healthy controls: A prospective case-control study in the Netherlands. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1267-1273.	1.3	34
78	DOP56 Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S063-S063.	1.3	34
79	Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1213-1231.	3.7	33
80	Fibrostenotic Phenotype of Myofibroblasts in Crohn's Disease is Dependent on Tissue Stiffness and Reversed by LOX Inhibition. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 849-859.	1.3	32
81	Novel Targets for Inflammatory Bowel Disease Therapeutics. <i>Current Gastroenterology Reports</i> , 2013, 15, 311.	2.5	31
82	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1578-1596.	3.7	31
83	Chromoendoscopy versus autofluorescence imaging for neoplasia detection in patients with longstanding ulcerative colitis (FIND-UC): an international, multicentre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 305-316.	8.1	31
84	Profoundly Expanded T-cell Clones in the Inflamed and Uninflamed Intestine of Patients With Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 831-839.	1.3	30
85	Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. <i>PLoS ONE</i> , 2018, 13, e0190999.	2.5	30
86	Validation and Investigation of the Operating Characteristics of the Ulcerative Colitis Endoscopic Index of Severity. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 937-944.	1.9	29
87	IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 167-180.	1.9	29
88	Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 484-506.	3.7	28
89	Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 265-276.	3.7	28
90	Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>BioDrugs</i> , 2021, 35, 715-733.	4.6	28

#	ARTICLE	IF	CITATIONS
91	Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1562-1571.	1.9	27
92	Diagnostic Accuracy of Transabdominal Ultrasound in Detecting Intestinal Inflammation in Paediatric IBD Patients: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1501-1509.	1.3	26
93	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 435-445.	3.7	26
94	TNF-anti-TNF Immune Complexes Inhibit IL-12/IL-23 Secretion by Inflammatory Macrophages via an Fc-dependent Mechanism. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1122-1130.	1.3	25
95	Bowel ultrasound measurements in healthy children – systematic review and meta-analysis. <i>Pediatric Radiology</i> , 2020, 50, 501-508.	2.0	25
96	Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 925-933.	1.3	24
97	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating $\gamma\delta$ T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 188-196.	1.3	24
98	Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 281-288.	1.5	24
99	The Risk of Colectomy and Colorectal Cancer After Appendectomy in Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 309-318.	1.3	22
100	Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1401-1409.	3.7	21
101	Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 930-938.	1.3	20
102	Immunogenicity of the Currently Recommended Pneumococcal Vaccination Schedule in Patients With Inflammatory Bowel Disease. <i>Clinical Infectious Diseases</i> , 2019, 70, 595-604.	5.8	20
103	High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1573-1582.e5.	4.4	20
104	Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2337-2346.e3.	4.4	20
105	Efficient Early Drug Development for Ulcerative Colitis. <i>Gastroenterology</i> , 2016, 150, 1056-1060.	1.3	19
106	Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2333-2342.	4.4	19
107	Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 106-118.	2.4	18
108	A phase II, Multicentre, Randomised, Double-Blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Efficacy of Amiselimod in Patients with Moderate to Severe Active Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 746-756.	1.3	18

#	ARTICLE	IF	CITATIONS
109	Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 304-313.	1.9	17
110	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2139-2141.e2.	4.4	17
111	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MAbs</i> , 2021, 13, 1868078.	5.2	17
112	Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 495-501.	1.9	17
113	Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 700-706.	1.5	16
114	Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1522-1531.	1.9	16
115	Natural History and Risk Stratification of Recurrent Crohn's Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1-8.	1.9	16
116	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.4	15
117	Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 947-954.e2.	4.4	15
118	Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 708-716.	1.3	15
119	A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn's disease patients. <i>PLoS ONE</i> , 2018, 13, e0209656.	2.5	14
120	Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 333-339.	3.7	14
121	The Role of the Lymphatic System in the Pathogenesis and Treatment of Inflammatory Bowel Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1854.	4.1	14
122	Standardisation of Study Protocols – Pros and Cons. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S553-S559.	1.3	13
123	Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 143-155.	3.0	13
124	Ulcerative Colitis: Shifting Sands. <i>Drugs in R and D</i> , 2019, 19, 227-234.	2.2	13
125	Impaired Quality of Working Life in Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2916-2924.	2.3	13
126	Intestinal Ultrasound to Evaluate Treatment Response During Pregnancy in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1045-1052.	1.9	13

#	ARTICLE	IF	CITATIONS
127	Emerging therapies for ulcerative colitis. Expert Review of Clinical Immunology, 2022, 18, 513-524.	3.0	13
128	Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflammatory Bowel Diseases, 2018, 24, 67-77.	1.9	12
129	Diagnostic Accuracy of Endoscopic Trimodal Imaging and Chromoendoscopy for Lesion Characterization in Ulcerative Colitis. Journal of Crohn's and Colitis, 2018, 12, 1438-1447.	1.3	12
130	Low interobserver agreement among endoscopists in differentiating dysplastic from non-dysplastic lesions during inflammatory bowel disease colitis surveillance. Scandinavian Journal of Gastroenterology, 2015, 50, 1011-1017.	1.5	11
131	Location but Not Severity of Endoscopic Lesions Influences Endoscopic Remission Rates in Crohn's Disease: A Post Hoc Analysis of TAILORIX. American Journal of Gastroenterology, 2021, 116, 134-141.	0.4	11
132	Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clinical Gastroenterology and Hepatology, 2022, 20, 2074-2082.	4.4	11
133	Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. Inflammatory Bowel Diseases, 2018, 24, 450-463.	1.9	10
134	Rational and clinical development of the anti-MAdCAM monoclonal antibody for the treatment of IBD. Expert Opinion on Biological Therapy, 2019, 19, 361-366.	3.1	10
135	Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflammatory Bowel Diseases, 2022, 28, 1034-1044.	1.9	10
136	Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease: Promising, but Work in Progress. Inflammatory Bowel Diseases, 2022, 28, 783-787.	1.9	9
137	Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, 224-243.	1.3	9
138	132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE. Gastroenterology, 2021, 160, S-37.	1.3	8
139	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. BMJ Open Gastroenterology, 2016, 3, e000092.	2.7	7
140	Golimumab for moderate to severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2017, 11, 401-406.	3.0	7
141	Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Alimentary Pharmacology and Therapeutics, 2018, 47, 773-783.	3.7	7
142	Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report. Clinical Case Reports (discontinued), 2019, 7, 2049-2053.	0.5	7
143	OP015 Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIRIC TRIAL. Journal of Crohn's and Colitis, 2017, 11, S9-S10.	1.3	6
144	Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's Disease. Inflammatory Bowel Diseases, 2022, 28, 1207-1218.	1.9	6

#	ARTICLE	IF	CITATIONS
145	Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Followed by the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) in Adults with and without Immunosuppressive Therapy. <i>Vaccines</i> , 2022, 10, 795.	4.4	6
146	P661 Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn's disease in the STEPSTONE trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S450-S450.	1.3	5
147	Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1321-1331.	1.9	5
148	Vedolizumab for the treatment of ulcerative colitis. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 423-430.	3.1	4
149	Case report of cheilitis granulomatosa and joint complaints as presentation of Crohn's disease. <i>Clinical Journal of Gastroenterology</i> , 2016, 9, 73-78.	0.8	4
150	Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. <i>Gastroenterology</i> , 2022, 162, 1005-1018.	1.3	4
151	PYRAMID registry: An observational study of adalimumab in Crohn's disease: results at year 3. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S21.	1.9	3
152	Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review. <i>Frontiers in Medicine</i> , 2020, 7, 600095.	2.6	3
153	Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 439-445.	1.5	3
154	Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S3-S4.	1.9	2
155	Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. <i>The Cochrane Library</i> , 2015, , .	2.8	2
156	Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives. <i>The Cochrane Library</i> , 2016, , .	2.8	2
157	Clinical disease activity in the CALM study – Authors' reply. <i>Lancet</i> , The, 2018, 391, 1482.	13.7	2
158	P687 Clinical remission demonstrated with oral ozanimod in the overall population and across multiple subgroups of patients with moderately to severely active ulcerative colitis in the TOUCHSTONE trial. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S464-S464.	1.3	2
159	How to Manage Crohn's Disease After Ileocolonic Resection?. <i>Gastroenterology</i> , 2020, 159, 816-820.	1.3	2
160	P757 Long-term effectiveness and safety of adalimumab based on Crohn's disease duration: Results from the PYRAMID registry. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S493-S494.	1.3	1
161	Intestinal and hepatic fibrosis: how are they similar?. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 820-822.	8.1	1
162	MRI scoring indices for evaluation of disease activity and severity in Crohn's disease. <i>The Cochrane Library</i> , 0, , .	2.8	0

#	ARTICLE	IF	CITATIONS
163	Reply. Gastroenterology, 2018, 155, 1278-1279.	1.3	0
164	Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. The Cochrane Library, 2018, , .	2.8	0
165	P380 A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX [®] for mild-to-moderate ulcerative colitis. Journal of Crohn's and Colitis, 2019, 13, S296-S297.	1.3	0
166	Patients' perspectives on a drug safety monitoring system for immune-mediated inflammatory diseases based on patient-reported outcomes. Expert Opinion on Drug Safety, 2021, 20, 1-8.	2.4	0
167	S0814 Endoscopic Healing Index Is Inversely Correlated With Serum Infliximab Concentrations in Crohn's Disease Patients: A Retrospective Analysis of the TAILORIX Clinical Trial Cohort. American Journal of Gastroenterology, 2020, 115, S418-S418.	0.4	0